Pricing Headwinds And Pipeline Setbacks Will Shadow RNAi Promise

Published
16 Apr 25
Updated
20 Aug 25
AnalystLowTarget's Fair Value
US$262.94
72.8% overvalued intrinsic discount
20 Aug
US$454.38
Loading
1Y
68.8%
7D
-0.5%

Author's Valuation

US$262.9

72.8% overvalued intrinsic discount

AnalystLowTarget Fair Value

Shared on07 May 25
Fair value Increased 0.47%

Shared on30 Apr 25
Fair value Increased 2.07%

AnalystLowTarget has increased profit margin from 6.0% to 8.7% and decreased future PE multiple from 185.6x to 129.6x.

Shared on23 Apr 25
Fair value Increased 0.074%

AnalystLowTarget made no meaningful changes to valuation assumptions.